Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion
NASDAQ:TYRA

Tyra Biosciences Q2 2024 Earnings Report

Tyra Biosciences logo
$33.02 -0.38 (-1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$33.01 -0.02 (-0.05%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tyra Biosciences EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.41
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Tyra Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tyra Biosciences Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
4:00PM ET

Tyra Biosciences Earnings Headlines

I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
Q3 Earnings Estimate for TYRA Issued By HC Wainwright
See More Tyra Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email.

About Tyra Biosciences

Tyra Biosciences (NASDAQ:TYRA) (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection.

Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.

View Tyra Biosciences Profile